Gerard Criner, MD, reviews GOLD 2026 sessions on mucus plugs and inhaler technique, plus multimorbidity, exacerbation risk, and the 2027 GOLD Report.
|Articles|March 17, 2010
NCCN 2010: Dr. David Pfister, Memorial Sloan-Kettering Cancer Center
Advertisement
David G. Pfister, MD of the Memorial Sloan-Kettering Cancer Center speaks about HPV and the Risk of Cancer at the 15th Annual NCCN Conference in Hollywood, FL March, 2010.
Advertisement
Related to this article
Lp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.
The FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.
In 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.
Advertisement
Advertisement
Trending on HCPLive
1
Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial Science
2
What’s New in the 2027 GOLD Report for COPD
3
Enlicitide Lowers LDL-C Consistently Across PREVENT CVD Risk Categories
4
Rezpegaldesleukin's Early Treg Signal in AD: Emma Guttman-Yassky, MD
5